01—Abstract
Summary
Summary of the 10-K filed February 13, 2025. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals (VRTX) closed 2024 with net product revenues of $11.0 billiona, up 12% from $9.9 billion in 2023, driven by TRIKAFTA/KAFTRIO demand, younger-age expansions, and higher U.S. net realized pricing.
However, reported results swung to a net loss of $535.6 millionb (-$2.08 per diluted share), versus net income of $3.6 billion in 2023. The swing was driven by a $4.4 billion non-deductible acquired in-process R&D charge from the May 2024 acquisition of Alpine Immune Sciences (for approximately $5.0 billion in cash) and its lead asset povetacicept, which was expensed as an asset acquisition. Excluding this charge, the underlying business remained highly profitable, though operating expenses rose sharply with R&D up 15% to $3.6 billion and SG&A up 29% to $1.5 billion.
Balance sheet liquidity fell as cash, equivalents and marketable securities declined to $11.2 billionc from $13.7 billion, reflecting the Alpine purchase and $1.2 billion of share repurchases. Operating cash flow was negative $492.6 million for 2024 (versus $3.5 billion in 2023), largely due to the Alpine payment. Management expects product revenues to grow in 2025 from ALYFTREK (approved December 2024, once-daily triple combination), CASGEVY infusions, and the January 2025 launch of JOURNAVX, a non-opioid acute pain drug.
The company has no debt drawn under its $500 milliond revolver and states cash flows should fund operations for at least twelve months. Key risks remain concentrated: substantially all product revenue comes from CF medicines, pricing pressure from the IRA and state PDABs, a December 2024 FDA boxed warning on liver injury for TRIKAFTA and ALYFTREK, and a pending patent trial against Lupin on KALYDECO granules scheduled for September 2025. The pipeline has several 2025 catalysts, including VX-522 mRNA data for CF, the AMPLITUDE and RAINIER interim analyses for potential accelerated approvals in AMKD and IgAN, and zimislecel Phase 3 enrollment in type 1 diabetes.
02—Key points
Key Highlights
- Net product revenues grew 12% to $11.0 billion in 2024, with TRIKAFTA/KAFTRIO reaching $10.2 billion (up 14%), while other CF products declined as patients switched to TRIKAFTA/KAFTRIO.
- GAAP net loss of $535.6 million (-$2.08 per diluted share) versus $3.6 billion net income in 2023, driven by the $4.4 billion non-deductible acquired IPR&D charge for the Alpine acquisition.
- Effective tax rate of 315.5% in 2024, distorted by the non-deductible Alpine IPR&D charge, versus 17.4% in 2023.
- Operating cash flow turned negative at -$492.6 million, compared with $3.5 billion in 2023, largely due to the approximately $5.0 billion Alpine cash payment.
- Total cash, equivalents and marketable securities declined 18% to $11.2 billion; the company repurchased $1.2 billion of stock in 2024 with $1.4 billion remaining under its $3.0 billion authorization.
- Launched or approved several new products in 2024-early 2025: ALYFTREK (CF, December 2024), expanded TRIKAFTA label (94 additional mutations), and JOURNAVX (non-opioid acute pain, January 2025), with CASGEVY now approved in eight jurisdictions.
- Concentration risk remains high: substantially all revenue comes from CF medicines, McKesson accounted for 26% of gross product revenue, and a Lupin patent trial on KALYDECO granules is scheduled for September 2025.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2024, Vertex Pharmaceuticals Inc lost $0.05.
- Revenue$11.02B100.0%
- Cost of revenue−$1.53B13.9%
- Gross profit$9.49B86.1%
- Operating costs−$9.72B88.2%
- Operating income−$232.9M2.1%
- Interest, other & tax−$302.7M2.7%
- Net income−$535.6M4.9%
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 13, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $11.02B$9.87B | +11.7% |
| Cost of Revenue | $1.53B$1.26B | +21.3% |
| Gross Profit | $9.49B$8.61B | +10.3% |
| SG&A Expenses | $1.46B$1.14B | +28.8% |
| Operating Expenses | $11.25B$6.04B | +86.4% |
| Operating Income | -$232.90M$3.83B | −106.1% |
| Net Income | -$535.60M$3.62B | −114.8% |
| EPS (Basic) | $-2.08$14.05 | −114.8% |
| EPS (Diluted) | $-2.08$13.89 | −115.0% |
| Shares Outstanding (Basic) | 257.90M257.70M | +0.1% |
| Shares Outstanding (Diluted) | 257.90M260.50M | −1.0% |
05—Questions
Frequently Asked Questions
Why did Vertex swing from a $3.6 billion profit in 2023 to a $535.6 million net loss in 2024?
The swing was primarily due to $4.6 billion of acquired in-process R&D expenses in 2024, of which $4.4 billion related to the Alpine Immune Sciences acquisition. Because Alpine was accounted for as an asset acquisition, the povetacicept value was expensed immediately and is non-deductible for tax purposes. Product revenue growth and higher operating costs also contributed, but the one-time IPR&D charge was the main driver.
How strong is Vertex's core business despite the 2024 loss?
The core CF franchise remains strong. Product revenues rose 12% to $11.0 billion, and TRIKAFTA/KAFTRIO grew 14% on global demand, younger-age expansions, and higher U.S. net pricing. Management estimates the five CF medicines are used by nearly three quarters of about 94,000 people with CF in the U.S., Europe, Australia and Canada, and expects further growth from ALYFTREK and new JOURNAVX and CASGEVY sales in 2025.
What are the main risks investors should monitor?
Key risks include reliance on CF revenue, with limited diversification so far; IRA drug price negotiation and state prescription drug affordability boards that may pressure pricing; a December 2024 FDA boxed warning on liver injury for TRIKAFTA and ALYFTREK; competition for CASGEVY from bluebird's gene therapies; and the Lupin patent litigation over KALYDECO granules, which goes to trial in September 2025. Reimbursement challenges outside the U.S. also remain a factor.
Can Vertex fund its operations and pipeline without new capital?
Management says cash on hand, marketable securities and product cash flows should be sufficient for at least the next twelve months. Liquidity declined to $11.2 billion, and operating cash flow was negative in 2024 due to the Alpine payment. The company has a $500 million undrawn revolving credit facility maturing in 2027, and it continues to repurchase shares, with $1.4 billion of authorization remaining, which will reduce cash if used.
What pipeline catalysts are expected in 2025?
Key 2025 catalysts include VX-522 (Moderna mRNA) multiple ascending dose data for CF in the first half, Part B full-dose data for VX-264 in type 1 diabetes, completion of enrollment in the zimislecel Phase 3 portion, and interim analyses from the AMPLITUDE (inaxaplin, AMKD) and RAINIER (povetacicept, IgAN) trials that could support accelerated approval filings in the U.S. The suzetrigine Phase 3 program in diabetic peripheral neuropathy is also ongoing, and a Phase 3 plan in lumbosacral radiculopathy is pending regulatory discussions.
06—Continue